FSN Capital buys Prange Group’s remaining stake in Adragos Pharma

• FSN Capital VI acquired Prange Group’s remaining shares in Adragos Pharma, taking full control alongside management.
• Prange Group exited its entire stake following a 2021 partnership that backed the CDMO’s expansion across Europe and Japan.
• Financial terms were not disclosed.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Adragos Pharma GmbH published the original content used to generate this news brief on September 21, 2026, and is solely responsible for the information contained therein.